{
    "organizations": [],
    "uuid": "a1e365b78dc7ae1859932400c580d58839527f1e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bristol-myers-says-opdivo-to-demon/brief-bristol-myers-says-opdivo-to-demonstrate-superior-survival-benefit-compared-with-chemotherapy-in-a-predominantly-chinese-population-with-previously-treated-non-small-cell-lung-cancer-idUSFWN1RQ0XC",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 13, 2018 / 8:46 PM / Updated 5 minutes ago BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer Reuters Staff 1 Min Read \nApril 13 (Reuters) - Bristol-Myers Squibb Co: \n* OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON -SMALL CELL LUNG CANCER (NSCLC) \n* IN PHASE 3 CHECKMATE-078 TRIAL, OPDIVO REDUCED RISK OF DEATH BY 32% VERSUS CHEMOTHERAPY \n* IN STUDY, OPDIVO DEMONSTRATED A STATISTICALLY SIGNIFICANT BENEFIT VERSUS DOCETAXEL ON PRIMARY ENDPOINT OF OVERALL SURVIVAL \n* IN TRIAL, TWO SECONDARY ENDPOINTS OF ORR, MEDIAN DURATION OF RESPONSE DEMONSTRATED DURABILITY WITH OPDIVO VERSUS DOCETAXEL Source text for Eikon: Further company coverage:",
    "published": "2018-04-13T23:45:00.000+03:00",
    "crawled": "2018-04-13T23:56:01.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "opdivo",
        "demonstrate",
        "superior",
        "survival",
        "benefit",
        "compared",
        "chemotherapy",
        "predominantly",
        "chinese",
        "population",
        "previously",
        "treated",
        "non",
        "small",
        "cell",
        "lung",
        "cancer",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "squibb",
        "co",
        "opdivo",
        "nivolumab",
        "first",
        "inhibitor",
        "demonstrate",
        "superior",
        "survival",
        "benefit",
        "compared",
        "chemotherapy",
        "predominantly",
        "chinese",
        "population",
        "previously",
        "treated",
        "non",
        "cell",
        "lung",
        "cancer",
        "nsclc",
        "phase",
        "trial",
        "opdivo",
        "reduced",
        "risk",
        "death",
        "versus",
        "chemotherapy",
        "study",
        "opdivo",
        "demonstrated",
        "statistically",
        "significant",
        "benefit",
        "versus",
        "docetaxel",
        "primary",
        "endpoint",
        "overall",
        "survival",
        "trial",
        "two",
        "secondary",
        "endpoint",
        "orr",
        "median",
        "duration",
        "response",
        "demonstrated",
        "durability",
        "opdivo",
        "versus",
        "docetaxel",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}